PRRSV

PRRSV

Porcine Reproductive and Respiratory Syndrome (PRRSV) continues to be one of the most frustrating challenges that veterinarians and producers face. Veterinarians often take a unique approach to PRRSV vaccination compared to other viruses. Some have found success with a protocol that includes an initial MLV commercial product followed by killed autogenous vaccine:

  • Viral strains in commercial products may not be as relevant as they should be, due to the length of time required to gain licensure
  • Quick turnaround on killed autogenous manufacturing enables the homologous strain to be included while still relevant in the herd
  • Inactivated vaccines tend to be less immunogenic against PRRSV compared with MLV products
  • Thus, a combination of the two may be the best option to overcome the downsides of each individual type of product
Vaccines manufactured by Cambridge Technologies have been proven time and time again to offer a “boost” to gilts and sows.

Leading swine veterinarians have partnered with Cambridge Technologies to research how autogenous vaccines can be used to lessen the effects of PRRSV on herds.

Click Here to download a recent study examining the success of the “prime-boost” protocol.

Click Here to download a recent study examining the effect of a quadrivalent heterologous inactivated PRRSV vaccine on time-to-stability for an infected breeding herd that has undergone an elimination program.